Mouse cardiac acyl coenzyme A synthetase 1 deficiency impairs fatty acid oxidation and induces cardiac hypertrophy

Molecular and Cellular Biology

Volumn 31, Issue 6, 2011, Pages 1252-1262

  Ellis, Jessica M ^a   Mentock, Shannon M ^a   DePetrillo, Michael A ^a   Koves, Timothy R ^b   Sen, Shiraj ^c   Watkins, Steven M ^d   Muoio, Deborah M ^b   Cline, Gary W ^e   Taegtmeyer, Heinrich ^c   Shulman, Gerald I ^e   Willis, Monte S ^f   Coleman, Rosalind A ^a  

^a The University of North Carolina at Chapel Hill   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d Lipomics Technologies Inc   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A SYNTHETASE; CARNITINE; ESTROGEN RELATED RECEPTOR ALPHA; GLUCOSE; LONG CHAIN FATTY ACID COENZYME A LIGASE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOCHONDRIAL DNA; PALMITIC ACID; S6 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FATTY ACID OXIDATION; GLUCOSE OXIDATION; GLYCOLYSIS; HEART MITOCHONDRION; HEART VENTRICLE HYPERTROPHY; HOMOGENATE; LIPID STORAGE; MAMMAL; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; SYNTHESIS;

ACYL COENZYME A; ANIMALS; CARDIOMEGALY; COENZYME A LIGASES; FATTY ACIDS; GENE DELETION; GLUCOSE; LIPID METABOLISM; MICE; MYOCARDIUM; OXIDATION-REDUCTION; TOR SERINE-THREONINE KINASES;

MAMMALIA; MUS;

EID: 79952267150     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01085-10     Document Type: Article

References (50)

1. An, J., et al. 2004. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nat. Med. 10:268-274.
2. Avruch, J., et al. 2009. Amino acid regulation of TOR complex 1. Am. J. Physiol. Endocrinol. Metab. 296:E592-E602.
3. Balasubramanian, S., et al. 2009. mTOR in growth and protection of hypertrophying myocardium. Cardiovasc. Hematol. Agents Med. Chem. 7:52-63.
4. Black, P. N., and C. C. DiRusso. 2003. Transmembrane movement of exogenous long-chain fatty acids: proteins, enzymes, and vectorial esterification. Microbiol. Mol. Biol. Rev. 67:454-472.
5. Bu, S. Y., M. T. Mashek, and D. G. Mashek. 2009. Suppression of long chain acyl-CoA synthetase 3 decreases hepatic de novo fatty acid synthesis through decreased transcriptional activity. J. Biol. Chem. 284:30474-30483.
6. Cao, A., H. Li, Y. Zhou, M. Wu, and J. Liu. 2010. Long chain acyl-CoA synthetase-3 is a molecular target for peroxisome proliferator-activated receptor delta in HepG2 hepatoma cells. J. Biol. Chem. 285:16664-16674.
7. Chen, Y., D. Xing, W. Wang, Y. Ding, and L. Du. 2007. Development of an ion-pair HPLC method for investigation of energy charge changes in cerebral ischemia of mice and hypoxia of Neuro-2a cell line. Biomed. Chromatogr. 21:628-634.
8. Chiu, H. C., et al. 2001. A novel mouse model of lipotoxic cardiomyopathy. J. Clin. Invest. 107:813-822.
9. Clark, H., D. Carling, and D. Saggerson. 2004. Covalent activation of heart AMP-activated protein kinase in response to physiological concentrations of long-chain fatty acids. Eur. J. Biochem. 271:2215-2224.
10. Coleman, R. A., T. M. Lewin, C. G. Van Horn, and M. R. Gonzalez-Baró. 2002. Do acyl-CoA synthetases regulate fatty acid entry into synthetic versus degradative pathways? J. Nutr. 132:2123-2126.
11. Cox, K. B., et al. 2009. Cardiac hypertrophy in mice with long-chain acyl-CoA dehydrogenase or very long-chain acyl-CoA dehydrogenase deficiency. Lab. Invest. 89:1348-1354.
12. Cunningham, J. T., et al. 2007. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 450:736-740. (Pubitemid 350207689)
13. de Jong, H., A. C. Neal, R. A. Coleman, and T. M. Lewin. 2007. Ontogeny of mRNA expression and activity of long-chain acyl-CoA synthetase (ACSL) isoforms in Mus musculus heart. Biochim. Biophys. Acta 1771:75-82.
14. Diniz, G. P., M. S. Carneiro-Ramos, and M. L. Barreto-Chaves. 2009. Angiotensin type 1 receptor mediates thyroid hormone-induced cardiomyocyte hypertrophy through the Akt/GSK-3beta/mTOR signaling pathway. Basic Res. Cardiol. 104:653-667.
15. Ellis, J. M., et al. 2010. Adipose acyl-CoA synthetase-1 (ACSL1) directs fatty acids towards β-oxidation and is required for cold thermogenesis. Cell Metab. 12:53-64.
16. Essop, M. F., et al. 2008. Reduced heart size and increased myocardial fuel substrate oxidation in ACC2 mutant mice. Am. J. Physiol. Heart Circ. Physiol. 295:H256-H265.
17. Exil, V. J., et al. 2003. Very-long-chain acyl-coenzyme A dehydrogenase deficiency in mice. Circ. Res. 93:448-455.
18. Ghatpande, S., S. Goswami, E. Mascareno, and M. A. Siddiqui. 1999. Signal transduction and transcriptional adaptation in embryonic heart development and during myocardial hypertrophy. Mol. Cell. Biochem. 196:93-97.
19. Glatz, J. F., and J. H. Veerkamp. 1982. Postnatal development of palmitate oxidation and mitochondrial enzyme activities in rat cardiac and skeletal muscle. Biochim. Biophys. Acta 711:327-335.
20. Graham, B. H., et al. 1997. A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator. Nat. Genet. 16:226-234.
21. Huang, J., and B. D. Manning. 2009. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem. Soc. Trans. 37:217-222.
22. Ingwall, J. S. 2009. Energy metabolism in heart failure and remodelling. Cardiovasc. Res. 81:412-419.
23. Inoki, K., et al. 2006. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126:955-968. (Pubitemid 44310775)
24. Kemi, O. J., et al. 2008. Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy. J. Cell. Physiol. 214:316-321.
25. Kuzman, J. A., T. D. O'Connell, and A. M. Gerdes. 2007. Rapamycin prevents thyroid hormone-induced cardiac hypertrophy. Endocrinology 148:3477-3484.
26. Lang, G., and G. Michal. 1974. D-Glucose-6-phosphate and D-fructose-6-phosphate, p. 1316-1319. In H. U. Bergmeyer (ed.), Methods of enzymatic analysis. Verlag Chemie International, Deerfield Beach, FL.
27. Lee, C. H., K. Inoki, and K. L. Guan. 2007. mTOR pathway as a target in tissue hypertrophy. Annu. Rev. Pharmacol. Toxicol. 47:443-467.
28. Li, L. O., et al. 2009. Liver-specific loss of long chain acyl-CoA synthetase-1 decreases triacylglycerol synthesis and beta-oxidation and alters phospholipid fatty acid composition. J. Biol. Chem. 284:27816-27826.
29. Li, L. O., et al. 2006. Overexpression of rat long chain acyl-CoA synthetase 1 alters fatty acid metabolism in rat primary hepatocytes. J. Biol. Chem. 281:37246-37255.
30. Makowski, L., et al. 2009. Metabolic profiling of PPARalpha-/- mice reveals defects in carnitine and amino acid homeostasis that are partially reversed by oral carnitine supplementation. FASEB J. 23:586-604.
31. Manfredi, G., L. Yang, C. D. Gajewski, and M. Mattiazzi. 2002. Measurements of ATP in mammalian cells. Methods 26:317-326. (Pubitemid 34971571)
32. Mashek, D. G., M. A. McKenzie, C. G. Van Horn, and R. A. Coleman. 2006. Rat long chain acyl-CoA synthetase 5 increases fatty acid uptake and partitioning to cellular triacylglycerol in McArdle-RH7777 cells. J. Biol. Chem. 281:945-950.
33. McMullen, J. R., and G. L. Jennings. 2007. Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin. Exp. Pharmacol. Physiol. 34:255-262.
34. Melegh, B., et al. 2004. Phenotypic manifestations of the OCTN2 V295X mutation: sudden infant death and carnitine-responsive cardiomyopathy in Roma families. Am. J. Med. Genet. A 131:121-126.
35. Mirebeau-Prunier, D., et al. 2010. Estrogen-related receptor alpha and PGC-1-related coactivator constitute a novel complex mediating the biogenesis of functional mitochondria. FEBS J. 277:713-725.
36. Neschen, S., et al. 2005. Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 knock out mice. Cell Metab. 2:55-65. (Pubitemid 43239825)
37. Noland, R. C., et al. 2007. Peroxisomal-mitochondrial oxidation in a rodent model of obesity-associated insulin resistance. Am. J. Physiol. Endocrinol. Metab. 293:E986-E1001.
38. Polokoff, M. A., and R. M. Bell. 1978. Limited palmitoyl-CoA penetration into microsomal vesicles as evidenced by a highly latent ethanol acyltransferase activity. J. Biol. Chem. 253:7173-7178.
39. Rupp, H., and R. Jacob. 1992. Metabolically-modulated growth and phenotype of the rat heart. Eur. Heart J. 13(Suppl. D):56-61.
40. Saha, A. K., et al. 2010. Downregulation of AMPK accompanies leucine- and glucose-induced increases in protein synthesis and insulin resistance in rat skeletal muscle. Diabetes 59:2426-2434.
41. Sharma, S., P. H. Guthrie, S. S. Chan, S. Haq, and H. Taegtmeyer. 2007. Glucose phosphorylation is required for insulin-dependent mTOR signalling in the heart. Cardiovasc. Res. 76:71-80.
42. Soesanto, W., et al. 2009. Mammalian target of rapamycin is a critical regulator of cardiac hypertrophy in spontaneously hypertensive rats. Hypertension 54:1321-1327.
43. Stanley, W. C., F. A. Recchia, and G. D. Lopaschuk. 2005. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 85:1093-1129.
44. Stansfield, W. E., et al. 2007. Characterization of a model to independently study regression of ventricular hypertrophy. J. Surg. Res. 142:387-393.
45. Suenaga, M., et al. 2004. Identification of the up- and down-regulated genes in the heart of juvenile visceral steatosis mice. Biol. Pharm. Bull. 27:496-503.
46. Sun, X., et al. 2009. Nicotine stimulates PPARbeta/delta expression in human lung carcinoma cells through activation of PI3K/mTOR and suppression of AP-2alpha. Cancer Res. 69:6445-6453.
47. Taylor, E. B., W. J. Ellingson, J. D. Lamb, D. G. Chesser, and W. W. Winder. 2005. Long-chain acyl-CoA esters inhibit phosphorylation of AMP-activated protein kinase at threonine-172 by LKB1/STRAD/MO25. Am. J. Physiol. Endocrinol. Metab. 288:E1055-E1061.
48. Tong, F., P. N. Black, R. A. Coleman, and C. C. DiRusso. 2006. Fatty acid transport by vectorial acylation in mammals: roles played by different isoforms of rat long-chain acyl-CoA synthetases. Arch. Biochem. Biophys. 447:46-52.
49. van der Vusse, G. J., J. F. Glatz, H. C. Stam, and R. S. Reneman. 1992. Fatty acid homeostasis in the normoxic and ischemic heart. Physiol. Rev. 72:881-940.
50. Watkins, S. M., P. R. Reifsnyder, H. J. Pan, J. B. German, and E. H. Leiter. 2002. Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. J. Lipid Res. 43:1809-1817.